Get respiratory testing resources
The answer to your respiratory testing needs
The symptoms of flu, COVID-19 and other respiratory infections are all very similar, making them difficult to diagnose. Sensitive multiplex PCR panel testing is a fast and simple way to accurately diagnose your patients when multiple respiratory pathogens are circulating. In fact, the CDC and The Academy of Medical Sciences “strongly support multiplex testing” in this situation (10, 11).
With the QIAstat-Dx Respiratory SARS-CoV-2 Panel, you don’t just get results for 21 respiratory pathogens in about an hour. You also get access to Ct values and amplification curves, powerful connectivity features and on-demand epidemiology reports.
Get in touch – we’re ready to help you
Our team of experts is ready to help you bring the reliability of QIAstat-Dx multiplex panel testing to your lab. Contact us to see how.
Additional resources
References
- Zhang, Y., Yakob, L., Bonsall, M.B., Hu, W. (2019) Predicting seasonal influenza epidemics using cross-hemisphere influenza surveillance data and local internet query data. Scientific Reports 9, 3262.
- The Guardian. Australia’s monthly flu cases more than doubled previous record in May. https://www.theguardian.com/australia-news/2022/jun/12/australias-monthly-flu-cases-more-than-doubled-previous-record-in-may
- Weekly U.S. Influenza Surveillance Report | CDC. https://www.cdc.gov/flu/weekly/index.htm
- CDC COVID Data Tracker: Daily and Total Trends. https://covid.cdc.gov/covid-data-tracker/#trends_dailycases_select_00
- Respiratory Adenovirus National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/adeno/natl-trend.html
- Human Metapneumovirus National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/hmpv/natl-trend.html
- Human Parainfluenza National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/human-paraflu/natl-trend.html
- RSV National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html
- Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 10325: 629–655
- Academy of Medical Sciences (2021) COVID-19: Preparing for the future – Looking ahead to winter 2021/22 and beyond. https://acmedsci.ac.uk/file-download/4747802
- CDC. Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians-hospitaized.htm
* Some features require a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
- This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
- This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declarations is terminated or authorization is revoked sooner.